Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BHV-8000 · 1 trial · 1 indication
To evaluate the efficacy of BHV-8000 compared to placebo. This objective is measured by assessing the time to prespecified worsening on MDS-UPDRS Part II (motor experiences of daily living per self-administered questionnaire). MDS-UPDRS Part II is a 52-point scale with a higher total score representing more severe disability.
| Arm | Type | Description |
|---|---|---|
| BHV-8000 10 mg | EXPERIMENTAL | Double-blind (DB) Phase (Randomization through Week 48): Participants will receive blinded IP. Open-label Phase: Participants will receive BHV-8000. |
| BHV-8000 20 mg | EXPERIMENTAL | Double-blind (DB) Phase (Randomization through Week 48): Participants will receive blinded IP. Open-label Phase: Participants will receive BHV-8000. |
| Placebo | PLACEBO_COMPARATOR | Double-blind (DB) Phase (Randomization through Week 48): Participants will receive blinded IP (matching placebo). Open-label Phase: Participants will receive BHV-8000. |
| Name | Type | Description |
|---|---|---|
| BHV-8000 10mg | DRUG | taken orally |
| BHV-8000 20 mg | DRUG | taken orally |
| Placebo | DRUG | taken orally |
Key Inclusion Criteria: * Male or female participants 40 to 80 years of age, inclusive, at the time of informed consent. * Meet the diagnostic criteria for "Probable PD" as assessed on the Movement Disorder Society (MDS) Clinical Diagnostic Criteria for PD as assessed by the Investigator. * Have a ...
Top 12 of 20 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | SUPN | 2 | PHASE3 | Onapgo (SPN-830) |
| Prothena Corp. Plc | PRTA | 3 | PHASE3 | Prasinezumab |
| Biohaven Ltd. | BHVN | 1 | PHASE2 | BHV-8000 |
| Denali Therapeutics Inc. | DNLI | 1 | PHASE2 | BIIB122 |
| AC Immune SA | ACIU | 2 | PHASE2 | ACI-7104.056 |
| Gain Therapeutics, Inc. | GANX | 2 | PHASE2 | GT-02287 |
| Eli Lilly and Company | LLY | 3 | PHASE1 | LY3884961, LY4006896, LY3962681 |
| Annovis Bio Inc | ANVS | 1 | PHASE2 | Buntanetap |
| Regeneron Pharmaceuticals, Inc. | REGN | 2 | PHASE1 | ALN-SNCA |
| MeiraGTx Holdings Plc | MGTX | 1 | PHASE1 | AAV-GAD |
| AgeX Therapeutics, Inc. | SER | 1 | PHASE1 | SER-252 |
| Ardelyx, Inc. | ARDX | 1 | PHASE2 | Tenapanor |
BHV-8000 is an investigational small molecule being developed for the treatment of early Parkinson's disease. It is currently in Phase 2 clinical development and is being studied in adults living with early Parkinson's disease. The drug is not yet approved and remains under investigation.
BHV-8000 targets TYK2 and JAK1, which are kinases involved in cellular signaling. By inhibiting these targets, the drug may modulate inflammatory pathways relevant to Parkinson's disease. This mechanism is being evaluated in clinical trials to determine its safety and effectiveness.
BHV-8000 is being developed by Biohaven Ltd., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol BHVN. The company is conducting clinical research to evaluate the drug's potential as a treatment for early Parkinson's disease.
BHV-8000 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The ongoing Phase 2 trial is recruiting participants to assess the drug's effectiveness, safety, and tolerability in adults with early Parkinson's disease.
BHV-8000 is being studied in a Phase 2 clinical trial with the identifier NCT06976268. This randomized, double-blind, placebo-controlled study is recruiting approximately 550 participants in the United States. The trial is evaluating the drug's effectiveness, safety, and tolerability in adults with early Parkinson's disease.